Fondation A. de Rothschild

Running trials

• Not yet recruiting

  A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.

  2026-525161-40-00· Phase 2· Source

• Not yet recruiting

  A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.

  2026-525162-21-00· Phase 2· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· Source

• Recruiting

  Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring

  2024-519133-29-00· Phase 2· Source

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07463521· Phase 3· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  NCT07441642· Phase 2· Source

• Recruiting

  Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· Phase 3· Source

• Recruiting

  Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION)

  2024-519521-37-01· Phase 2/3· Source

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Source

• Active, not recruiting

  A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06957080· Phase 2/3· Source

• Not yet recruiting

  Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

  NCT06663189· Phase 3· Source

• Active, not recruiting

  A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)

  2024-510944-30-00· Phase 2/3· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

  NCT06558279· Phase 3· Source

• Recruiting

  Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  NCT06463587· Phase 3· Source

• Recruiting

  Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis

  NCT05476991· Phase 3· Source

• Recruiting

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

  NCT05716100· Phase 3· Source

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Source

• Recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  NCT05667142· Phase 3· Source

• Recruiting

  Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

  NCT05476939· Phase 3· Source

• Recruiting

  Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT05327114· Phase 2/3· Source

• Recruiting

  Stenting Versus Neurosurgical Treatment of Idiopathic Intracranial Hypertension.

  NCT05050864· Source

• Recruiting

  Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke

  NCT05105633· Phase 2/3· Source

• Active, not recruiting

  A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

  NCT04657289· Phase 3· Source

• Recruiting

  RESting-state Functional MRI for Prediction of Post-surgical Prognosis In Pediatric Drug-Resistant Epilepsy

  NCT04451278· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Source

• Recruiting

  Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?

  NCT03267459· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy7 recruiting
• Macular degeneration4 recruiting
• Multiple sclerosis4 recruiting
• Myasthenia gravis3 recruiting
• Stroke3 recruiting
• Childhood cancers2 recruiting
• Coronary artery disease1 recruiting
• High blood pressure1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP

  2024-515386-34-00· Phase 2· Source

• Completed

  Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial

  NCT04667078· Phase 4· Source

• Completed

  Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study

  NCT05559398· Phase 2/3· Source

• Completed

  Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

  NCT05536297· Phase 3· Source

• Completed

  Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target)

  NCT04785066· Phase 2· Source

• Completed

  A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

  NCT05019521· Phase 2· Source

• Completed

  Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis

  NCT03963310· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Source